J Allergy Clin Immunol:IgE对鼻息肉有影响么?

2021-04-15 AlexYang MedSci原创

最近,有研究人员采用叙述性综述的一种新的方法,整理了有关鼻息肉的知识和IgE在几种疾病(过敏性鼻炎、过敏性哮喘、非甾体抗炎药物加重的呼吸道疾病[N-ERD]和慢性自发性荨麻疹)中的生物学功能,从而考虑

最近,有研究人员采用叙述性综述的一种新的方法,整理了有关鼻息肉的知识和IgE在几种疾病(过敏性鼻炎、过敏性哮喘、非甾体抗炎药物加重的呼吸道疾病[N-ERD]和慢性自发性荨麻疹)中的生物学功能,从而考虑哪些IgE介导的机制与鼻息肉病理相关

研究结果表明,在欧洲鼻息肉患者的鼻息肉组织中,以嗜酸性粒细胞为主的2型(T2)炎症特征是典型的,近年来在亚洲人群中观察到了向这种分型的转变。在有过敏和无过敏患者的鼻腔组织中,多克隆IgE升高。它来源于许多不同的B细胞克隆,重要的是,它是功能性的(促炎)。

金黄色葡萄球菌(SA)肠毒素被认为是作为超抗原,通过B细胞和T细胞激活诱导多克隆IgE的产生,并引发炎症介质的释放。在一些患者中,暴露于抗原/诱因导致产生高水平的抗原特异性IgE,它能介导多种细胞上的高亲和力IgE受体(FcεRI)交联,导致炎症介质的释放。

鼻息肉病中IgE的产生和功能

另外,奥马珠单抗的疗效证实了IgE是鼻息肉的重要炎症介质。通过靶向所有游离IgE,奥马利珠单抗可以缩小鼻息肉大小,改善症状,并抑制潜在的T2炎症。

原始出处:

Claus Bachert , Marcus Maurer , Oscar Palomares et al. What is the contribution of IgE to nasal polyposis? J Allergy Clin Immunol. Mar 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=957515, encodeId=dc8d95e515af, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略! , beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 10:08:58 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329489, encodeId=c843132948982, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Apr 17 13:39:59 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426405, encodeId=2831142640520, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Sat Apr 17 13:39:59 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957527, encodeId=3fab95e52701, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Apr 16 10:25:56 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 七安

    三人行,必有我师。 #梅斯医学科研互助群# 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=957515, encodeId=dc8d95e515af, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略! , beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 10:08:58 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329489, encodeId=c843132948982, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Apr 17 13:39:59 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426405, encodeId=2831142640520, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Sat Apr 17 13:39:59 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957527, encodeId=3fab95e52701, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Apr 16 10:25:56 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-17 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=957515, encodeId=dc8d95e515af, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略! , beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 10:08:58 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329489, encodeId=c843132948982, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Apr 17 13:39:59 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426405, encodeId=2831142640520, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Sat Apr 17 13:39:59 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957527, encodeId=3fab95e52701, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Apr 16 10:25:56 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-17 zhenjiu124
  4. [GetPortalCommentsPageByObjectIdResponse(id=957515, encodeId=dc8d95e515af, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略! , beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 10:08:58 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329489, encodeId=c843132948982, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Apr 17 13:39:59 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426405, encodeId=2831142640520, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Sat Apr 17 13:39:59 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957527, encodeId=3fab95e52701, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Apr 16 10:25:56 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 ms3000000449926787

    已读

    0

相关资讯

Cell:髓系细胞免疫信号枢纽——TREM2

阿尔茨海默症,肥胖相关的代谢综合症和肿瘤是当今导致死亡的主要原因。 最新的研究表明,在这些疾病情况下, TREM2作为病理学诱导的免疫信号枢纽,可响应组织损伤,并进行免疫重塑。

Blood:在多发性骨髓瘤中,单克隆免疫球蛋白促进骨丢失

骨髓瘤合并骨病患者的单克隆免疫球蛋白的IgG Fc糖基化减少,促进破骨细胞分化;在骨髓瘤小鼠模型中,用N-乙酰甘露糖胺治疗可增加IgG唾液酸苷化,减少骨髓瘤溶骨损伤的数量和肿瘤负荷。

免疫球蛋白Octagam治疗严重COVID-19患者:FDA已批准研究性新药申请

Octagam是一款人免疫球蛋白液体制剂,用于治疗成人慢性免疫性血小板减少性紫癜(ITP)。

Lancet Neurology:预后不良的吉兰-巴雷综合征(SID-GBS)患者的第二次静脉注射免疫球蛋白:一项双盲、随机、安慰剂对照试验

吉兰-巴雷综合征是一种免疫介导的多发性神经根性神经病,全球每年每10万人中就有0.81-1.89人受到影响。它通常是一种单相疾病,进展迅速,四肢无力,其临床严重程度、病程和预后各不相同。

NIH开展免疫球蛋白联合瑞德西韦治疗COVID-19

美国国立卫生研究院(NIH)国家过敏与传染病研究所(NIAID)已开展免疫球蛋白联合抗病毒药物瑞德西韦治疗COVID-19的III期临床试验(ITAC研究),以测试该联合方案的安全性、耐受性和有效性。

Int Arch Allergy Immunol:474名螨虫敏感患者中的Der P 23致敏分析

屋尘螨包括了一些过敏原组分,并能够引起常年过敏。最近,一种新的过敏原Der p 23在不同的欧洲国家具有相对较高的致敏比例。另外,Der p 23也被认为能够引起哮喘疾病。